IMPROVEMENT OF MOLECULAR TECHNOLOGIES AND PRENATAL DIAGNOSIS OF CYSTIC FIBROSIS  by Pelo, E. et al.
Posters S11
trans with a 5 thymidines (5T) sequence within the intron 8 Splice Variant (IVS8)
region. 5T is responsible of an exacerbated skipping of exon 9, decreasing the
functional product levels. It has been demonstrated that 5T phenotypic expression
is inﬂuenced by another adjacent polymorphic region, constituted by 9 to 13 TG
repeats. In particular, 5T/TG13 combination was found only in affected subjects.
Case Report: We report a case regarding two sisters, aged 23 and 18 years,
carriers of the F508del mutation associated with the 5T/TG13 combination. DHPLC
investigation did not detect a second mutation. Both sisters present mild pulmonary
symptoms started in puberty, bronchiectasis, pancreatic sufﬁciency and border-line
chloride values at the sweat test. However, they differ because the elder patient has
more evident bronchiectasis, and she also presents pansinusitis, a positive sputum
culture and a slightly reduced FEV1.
Conclusions: The natural history of non classic CF is poorly understood. It may be
asymptomatic for years but a signiﬁcant lung involvement may occur, as seen in the
elder sister. This ﬁnding suggests that a prevention therapy could be necessary also
in mild, non classic CF and an early diagnosis may prevent the organ deterioration,
as in the younger sister. Early diagnosis may be supported by TG repeats testing in
individuals carrying the 5T variant; in fact, our report conﬁrms that the presence of
5T allele, in trans with a severe CFTR mutation, is associated with non classic CF
and that TG13 variant acts as a real mild mutation, enhancing the 5T penetrance
and determining the onset of a mild symptomatology in all patients.
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Introduction: In recent years, an increasing number of subjects bearing “atypical”
forms of cystic ﬁbrosis (CF) associated with normal sweat chloride concentrations
has been described.
Objective: We report a case of an atypical form of CF observed in two sisters with
F508del/G576A + R668C complex CFTR genotype.
Methods: These patients were ﬁrst examined for a panel of 56 CF mutations with
Inno-Lipa reverse dot blot procedure (Innogenetics Belgium) and later with DGGE
of all exons of the CFTR gene using primers and the conditions described elsewhere
(Fanen P, et al. 1992. Genomics 13, 770–776; Costes B, et al. 1993. Hum Mol Genet
2, 1209–1213) followed by sequencing analysis to characterize the mutations.
Case: A 6-year-old female with recurrent episodes of asthma exacerbation came
to the Southern Italy referral CF Centre in October 2006. She did not present
symptoms of pancreatic insufﬁciency. However, she was hetereozygous for F508del
with a normal sweat chloride test (38mEq/L). After scanning the whole CFTR gene
we individuated other mutations: G576A (exon 12) and R668C (exon 13). On the
basis of these results, her sister (5-year-old) affected by recurrent episodes of upper
airway infections was also examined. She showed the same CFTR genotype of her
sister, her sweat chloride values were also normal (31mEq/L).
Discussion and Conclusion: The G576A, originally listed as a neutral polymor-
phism in CF Genetic Analysis Consortium (www.genet.sikkids.on ca./cftr/) is a
missense mutation that causes CFTR exon 12 skipping (Pagani F, et al. 2003. Hum
Mol Genet 12, 1111–1120). More recently, studies documented this mutation in
adults with classic forms of CF (Bienvenu T, et al. 1997.Ann Genet 40, 5−9) and
in patients who have evidence of a clinical disease only in a subgroup of the organ
systems (Ravnik-Glavac M, et al. 2000. Pﬂugers Arch 439, 53−55; Pignatti PF,
1995. Mol Genet 4, 635–639). These non classic CF forms, including late-onset
pulmonary disease, bronchiectasis, congenital bilateral absence of vas deferens
or idiopathic pancreatitis were associated with the presence of the G576A allele
combined with the R668C polymorphism. Our ﬁndings suggest that our patients
have the same described genetic arrangement but a longer period of follow-up is
needed to get deﬁnitive conclusions. How can we manage these cases in childhood?
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A 26-year-old subject with azoospermia was referred to our Center. The genetic
test at the ﬁrst level of screening showed heterozygosity for F508del.
From the history, symptoms suggestive of CF were present (three episodes of serious
dehydration, bronchopulmonary pathology, easy to become tired) therefore the sweat
test was performed and resulted pathological (Cl− 92/94), leading to a diagnosis
of CF.
In order to identify the second mutation the analysis of the entire coding sequence
of the CFTR gene was performed and we identiﬁed the mutation E831X, a G to T
transition at position 2623 in exon 14a. This mutation has been reported in Cystic
Fibrosis Database two cases (Ferec et al 1992).
General conditions of our patient are good, good nutritional status, PS and mild
lung disease.
Because exon 14a is the subject of alternative splicing (Hull et al., 1994) and
the mutation E831X is at the ﬁrst base of this exon we suppose that the mutation
caused a new site of splicing and increase its alternative splicing. Such a by-pass of a
premature termination codon has been shown to ameliorate the disease phenotype in
other clinical conditions (Morisaki et al., 1993; Ginjaar et al., 2000; Su et al., 2000).
Accurate history, sweat test and mutation analysis of CFTR gene have permitted to
reﬁne the diagnosis of CF in an azoospermic adult subject.
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A signiﬁcant percentage of CF alleles (ranging from 4 to 10%) remain unidentiﬁed
in most population, even after extensive studies of the CFTR gene by PCR based
procedure. At present time, CFTR mRNA analysis represents more a research tool
for the identiﬁcation of unknown molecular defects of the CFTR gene in speciﬁc
rare cases than a routine approach to complete a diagnostic procedure. In particular
mRNA analysis may allow researchers to establish the pathogenic role of sequence
variations not yet deﬁned like speciﬁc splicing defects. The results of our screening
for CFTR gene at DNA level, by DHPLC and MLPA analyses showed a mutation
detection rate of 94.4%. After this analysis, in our patients, 81 alleles (6%) were
still unknown. Aim of this work was to evaluate the role of the CFTR analysis at
mRNA level as a diagnostic method for the characterization of molecular defects
in patients affected by a classic form of CF, who still had one or two unidentiﬁed
alleles after an extensive analysis at DNA level. RNA was extracted with TRIzol
reagent, from nasal epithelial cells and collected using cyto-brush from 7 CF patients
and 3 non-CF controls. First strand cDNA was synthesized using hexanucleotide
primers and high capacity cDNA Archive kit. The cDNA was ampliﬁed in six
overlapping fragments spanning the entire gene and then visualized on agarose
gel for identifying large deletion/insertion and the product of possible alternatives
splicing; each fragment was next sequenced.
Disease-related mutations, not detected by DHPLC technique, were identiﬁed in two
patients; mRNA analysis performed on two other related patients with a deletion of
exon 2 at DNA level showed two novel transcription products carrying a deletion
of exon 2−3 and an insertion of intron sequence of about 80bp near exon 6b,
respectively. Two patients had low level of mRNA product and have to be analyzed
by quantitative technique. One patient showed a normal proﬁle. In conclusion our
data suggest that the defects at RNA level could explain the pathogenic role of
abnormal mRNA products in Cystic Fibrosis onset.
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Introduction: More than 1200 mutations and 200 polymorphisms have been
described for CFTR gene. Prenatal Diagnosis of Cystic Fibrosis (CF) must be
proposed to couples in which both partners are carriers of CFTR mutations and
thus the fetus is at one in four (1/4) risk of being affected.
Since 1989 the Centro di Riferimento Regionale Toscano per la Diagnosi Genetica
di Fibrosi Cistica has performed the characterization of CF patients together with
prenatal diagnosis for at-risk couples. The steps to be followed with prenatal
diagnosis will be as follows:
• Pre-test genetic counselling: to be performed before invasive procedures (am-
niocentesis or CVS) in order to advise the couples about the risk of prenatal
sampling and the accuracy of the genetic test for the diagnosis of CF.
• Post-test genetic counselling: to be performed in order to illustrate the results
obtained from the genetic test.
The at-risk couples are followed by a team composed by physicians, genetic
counsellor and other specialists.
Methods: Prenatal specimen types include both amniocytes and chorionic villi.
On the fetus’ DNA known mutations are detected by direct sequencing or OLA-
PCR; when mutations causing familial CF are unknown, CFTR gene is investigated
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concerning intragenic and/or extragenic SNPs. Maternal cell contamination is also
evaluated.
Results: Since 1998 a total of 52 at-risk couples have been supported by the Centro
di Riferimento Regionale Toscano per la Diagnosi Genetica di Fibrosi Cistica. On
44 out of 52 couples, a prenatal test has been performed. Affected fetus resulted
in 9 pregnancies; 2 resulted in a fetal loss after the prenatal sampling, the other
couples have decided for a fetus termination. 3 out of 8 couples, which have chosen
not to proceed with prenatal diagnosis, had spontaneous abortions; 4 out of 8 had
not affected or heterozygous children and only one had two affected children from
two different pregnancies.
Conclusions: The aim of the genetic counselling, which is an important step in
the CF diagnostic iter, is to offer at-risk couples the information concerning CF
hereditary pattern and to evaluate the recurrence risk. Considering that the majority
of couples ask a prenatal screening after the birth of an affected child, in order
to program the other pregnancies it is fundamental for laboratories to optimize the
different methods necessary for CF testing.
The success of CF prenatal diagnosis and other congenital diseases depends on the
effectiveness of a multidisciplinary approach as well as on the genetic counselling.
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Introduction: Lung disease and Pseudomonas aeruginosa (P. aeruginosa) airway
colonization represent a major cause of morbidity and mortality in cystic ﬁbrosis
(CF). Human b-defensin (hBD)-1 is believed to play an important role in mucosal
innate immunity in the lung.
Objective: This study aimed to investigate whether single nucleotide polymor-
phisms (SNPs) of the DEFB1 gene, coding for hBD-1, were associated with
P. aeruginosa airway colonization in CF.
Methods: A total of 182 CF patients bearing the severe/severe CFTR genotype
(carriers of classes I, II, III of CFTR gene mutations) were studied. The SNPs
G-52A, C-44G and G-20A in the 5’-untranslated region of the DEFB1 gene were
genotyped by use of polymerase chain reaction and restriction fragment length
polymorphism. Patients’ sputum samples were collected and analyzed by standard
methods.
Results: We found that carriers of the GA and AA genotypes at the −52 locus site
of the DEFB1 gene had an increased risk of P. aeruginosa chronic colonization than
carriers of the GG genotype (OR adjusted for age 3.21, 95% CI 1.12−9.23, p = 0.03).
Carrying the −44CC and the −20GG genotypes was not related to an increased risk
of colonization with P. aeruginosa as compared to carriers of the −44CG/GG and
the −20GA/AA genotypes, respectively, in this population (ORs adjusted for age
1.37, 95% CI 0.26−7.22 and 0.43, 95% CI 0.13−1.42, respectively; p=ns). Moreover,
in this group of CF patients the ACG haplotype was also signiﬁcantly associated
with P. aeruginosa chronic infection (OR adjusted for age 2.70, 95% CI 1.15−6.36,
p = 0.02).
Conclusion: These results indicate that variant alleles in DEFB1 might contribute
to the colonization of P. aeruginosa in CF.
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We report four cases of anomalous electropherograms obtained after PCR/OLA/SCS
analysis (Abbott), that led to the identiﬁcation of (a) three mutations: two considered
new mutations (E479X, G1247R(G>C)) and another mutation previously described
(I506V); (b) one polymorphism (2752−15C>G) all interfering with this analytical
procedure.
E479X and G1247R mutations were found in two CF subjects who, after
PCR/OLA/SCS, appeared homozygous for F508del and W1282X, although parents’
allelic segregation showed that the F508del and the W1282X mutations were present
in heterozygosity in one parent but absent in the other. Cycle sequencing (Applera)
of exons 10 (E479X) and 20 (G1247R) showed that these subjects were compound
heterozygotes F508del/E479X and W1282X/G1247R(G>C).
E479X mutation originates by nucleotidic change G>T at 1567 in exon 10 with
consequent Glu to Stop change at 479. This CF patient was diagnosed at 1 year
of age by symptoms; he is PI, with sweat chloride at 106mmol/l and moderate
pulmonary disease.
The aminoacidic substitution G1247R has already been described as a disease-
causing CFTR mutation originated by nucleotidic substitution 3871G>A; in this
case, instead, it originates from a 3871G>C nucleotidic substitution, with conse-
quent Glu to Arg change at 1247. This is a causing disease mutation and was found
in a CF patient diagnosed by neonatal screening; she is PS with sweat chloride at
78mmol/l and mild pulmonary disease.
The I506V mutation (previously reported as polymorphism 1648AorG) was found
in the mother of a heterozygous newborn carring F508del. This parent appeared
homozygous for F508del mutation while cycle sequencing of exon 10 showed that
she was compound heterozygous F508del/I506V. Also 2752−15C>G polymorphism
was found during parents’ allelic segregation of a heterozygous newborn carring
2789+5G>A. The mother appeared homozygous for 2789+5G>A mutation while
cycle sequencing of exon 14b (and proximal intronic regions) showed that this
subject had 2789+5G>A on an allele and 2752−15C>G on the other one.
Anomalous electrophoretic patterns of PCR/OLA/SCS assay and inconsistent par-
ents’ allelic segregation have to be checked for sequence variations, possibly
interfering with PCR primers or OLA probes; this should radically reduce wrong
genetic characterizations.
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Introduction: The regulation of the CFTR gene expression has been object of
numerous studies, because in a percentage of CF patients the disease is caused by
alteration of the expression. The analysis of CFTR sequences revealed the absence
of TATA box, but the presence of multiple transcriptional sites. In 2001, a tissue-
speciﬁc DNase I hypersensitive site (DHS) in intron 1 (185+10 kb) of the CFTR
gene was identiﬁed that is required for CFTR expression in the intestinal epithelium,
and other intronic sites are target of regulatory factors. Other still unknown targets
of regulatory factors may be present in CFTR introns. Recently, a comparative
analysis (Homo Sapiens, Mouse, Rat, Zebraﬁsh, Fugu) revealed the presence of a
high number of conserved sequences in human genome. Our group identiﬁed the
‘conserved sequence tags’ (CSTs), i.e., genomic sequences that may be the result
of selective evolutionary pressure for conservation due to a possible functional
role (Boccia A, et al. Nucleic Acid Res, 2005). CST sequences show at least 70%
identity between human and mouse over a length of 100bp. Mutations in these
regions could be responsible of genetic diseases. About 100 CSTs were found in
coding and non-coding regions of CFTR.
Aims: To analyse 52 CFTR intronic CSTs in 37 CF patients bearing one or both
undetected mutations after CFTR gene scanning. CF patients with a known genotype
(n: 23), and non-CF subjects (n: 20) were included in the study as controls.
Methods: We performed multiplex PCR followed by direct sequencing of the 52
CSTs on the DNA extracted from the 90 subjects included in the study.
Results: The study demonstrated that 57.6% of the analysed regions did not show
changes, while in 42.3% of the regions were observed 41 gene variants, including
16 novel. Eleven variants (most novel) were speciﬁcally present in CF patients
bearing undetected mutations. Furthermore, we identiﬁed three novel intragenic
microsatellites: one CA repeat in IVS10 and two PolyA in IVS3 and IVS4
respectively, with a high heterozygosity.
Conclusion: CSTs gene variants might represent causative-mutations; to verify this
hypothesis we will undertake both computational analysis (with known regulatory
motif) and in vitro studies with the “ﬁshing for partners” strategies. The three novel
intragenic microsatellites can be used to improve CF linkage diagnosis.
Acknowledgments: Cystic Fibrosis Foundation of Verona, Italy, is gratefully
acknowledged.
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Introduction: The SLC26 (Solute Linked Carrier) are a gene family encoding
highly versatile anion exchangers, involved in many physiological processes, like
trans epithelial NaCl transport and bicarbonate secretion. Actually, about 10 proteins
belong to this family and some of them are related to human diseases, like
SLC26A3 that is the disease gene of a rare and severe form of chronic chloride
loosing diarrhoea (CLD). Two domains of SLC26A3 protein, the “STAS-like” and
PDZ domains, play a critical role in its activation and bicarbonate secretion. This
